Abstract:Abstract Background Evidence for central nervous system involvement in primary Sjögren’s syndrome (pSS) patients is controversial and extremely limited. We aimed to describe the clinical profiles and high-risk indicators of primary Sjögren’s syndrome (pSS) patients with central nervous system (CNS) involvement (pSS-CNS). Methods A total of 412 participants with pSS from a hospital in China from January 2012 to December 2019 were enrolled in the retrospective study. 42 pSS-CNS patients were compared with 370 pSS patients without CNS involvement. The clinical features, laboratory examinations, imaging characteristics, and treatment of the pSS-CNS cases were systematically analyzed. Potential risk factors related to pSS-CNS patients were identified by multivariate logistic regression analysis. Results The prevalence of central nervous system involvement in the studied pSS patients was 10.2% (42/412), with 31.3% (14/42) of pSS patients having neurological manifestations as the initial symptom. The manifestations of hemiparesis (35.7%, 15/42), paraparesis (28.6%, 12/42), dysphonia (31.0%, 13/42), blurred vision (21.4%, 9/42), and dysfunctional proprioception (23.8%, 10/42) were more common in the pSS-CNS patients. Cerebral infarction (57.1%, 24/42), demyelination (31.0%, 13/42), myelitis (23.8%, 11/42), and angiostenosis (21.4%, 9/42) were most often found on MRI or CT scan imaging in the pSS-CNS patients. Intrathecal IgG level and total protein of cerebrospinal fluid were increased in 50% (8/16) of the pSS-CNS group. In comparison with patients without CNS involvement, the pSS-CNS patients were found to also have kidney and lung involvement, hematologic abnormalities, positive ANA and anti-SSA antibody tests, and reduced complement 3 (C3) and complement 4 (C4) levels (all p < 0.05). The prevalence of lung involvement, immune thrombocytopenia, and high-titer ANA (1:1000) were significantly higher in pSS-CNS disease activity compared to those in the moderately active group. Multivariate analysis identified lung involvement, anti-SSA positivity, and low C3 levels as prognostic factors for pSS-CNS. After high-dose glucocorticoids and immunosuppressive therapy, 60.5% (26/38) of pSS-CNS patients improved, 36.8% (14/38) were unresponsive to treatment, and 2.6% (1/38) died. Conclusion Clinical features are diverse in pSS-CNS patients, and the morbidity rate is low. CNS involvement was the initial presentation in state percentage here pSS patients. Pulmonary involvement, a positive anti-SSA antibody test, and reduced C3 levels are potential risk factors for CNS involvement in pSS. Treatment with high-dose glucocorticoids and immunosuppressive therapy appeared effective in 60% of pSS-CNS patients. Key Points • The CNS manifestations of pSS are diverse, and CNS imaging and CSF analysis are important for the diagnosis. • Pulmonary involvement, positive anti-SSA, and reduced C3 levels are potential risk factors of pSS-CNS. • About 60% of pSS-CNS patients were responsive to high-dose glucocorticoid administration and immunosuppressive therapy.

Clinical stratification of 1318 Primary Sjögren's Syndrome patients

Biomarkers for Primary Sjögren’s Syndrome

Follicular Helper T Cells and Follicular Regulatory T Cells in the Immunopathology of Primary Sjögren's Syndrome

Characteristics of Primary Sjögren’s Syndrome Patients with IgG4 Positive Plasma Cells Infiltration in the Labial Salivary Glands

Single-cell transcriptomic analysis uncovers heterogeneity in the labial gland microenvironment of primary Sjögren's syndrome

Single-cell transcriptome profiling reveals immune and stromal cell heterogeneity in primary Sjögren’s syndrome

OP0185 Characteristics of Primary Sjögren's Syndrome Patients with IGG4-Positive Plasma Cells in Labial Salivary Glands

Characteristics of Chinese patients with primary Sjögren's syndrome: preliminary report of a multi-centre registration study.

Analysis of Gene Expression and TCR/B Cell Receptor Profiling of Immune Cells in Primary Sjögren's Syndrome by Single-Cell Sequencing.

POS0109 IDENTIFICATION OF PRIMARY SJOGREN’S SYNDROME SUBTYPES BY MACHINE LEARNING

Primary Sjögren syndrome in Han Chinese: clinical and immunological characteristics of 483 patients.

Seronegative primary Sjögren's syndrome, a distinct subtype of primary Sjögren's syndrome in Chinese patients

Analysis of Gene Expression and TCR/B Cell Receptor Profiling of Immune Cells in Primary Sjogren?s Syndrome by Single-Cell Sequencing

Patients with Early-Onset Primary Sjögren’s Syndrome Have Distinctive Clinical Manifestations and Circulating Lymphocyte Profiles

Clinical Characteristics of Distinct Subgroups of Patients with Primary Sjögren's Syndrome Classified by Serological Profiles: A Comparison Study

Anti-SSA/SSB-negative Primary Sjögren’s Syndrome Showing Different Clinical Phenotypes: a Retrospective Study of 934 Cases

The Serological Profiles of Subgroup of Primary Sjögren's Syndrome Correlation with the Clinical Features of Parotid Glands.

Clinical features and high-risk indicators of central nervous system involvement in primary Sjögren’s syndrome

Integrated Bioinformatics and Validation Reveal Potential Biomarkers Associated With Progression of Primary Sjögren's Syndrome

The clinical characteristics of 573 cases of primary Sj(o)gren's syndrome

Clinical analysis of the neurological involvement in primary Sj(o)gren's syndrome